Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of type 2 diabetes (T2D) and obesity, with injectable agents demonstrating significant cardiovascular (CV) risk reduction in pivotal trials including LEADER, SELECT, and SUMMIT. However, the reliance on injectable peptide formulati...